Exploiting Gene Expression Profiling to Identify Novel Minimal Residual Disease Markers of Neuroblastoma

Department of Pediatrics and Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
Clinical Cancer Research (Impact Factor: 8.19). 11/2008; 14(21):7020-7. DOI: 10.1158/1078-0432.CCR-08-0541
Source: PubMed

ABSTRACT Minimal residual disease (MRD) presents a significant hurdle to curing metastatic neuroblastoma. Biological therapies directed against MRD can improve outcome. Evaluating treatment efficacy requires MRD measurement, which serves as surrogate endpoint. Because of tumor heterogeneity, no single marker will likely be adequate. Genome-wide expression profiling can uncover potential MRD markers differentially expressed in tumors over normal marrow/blood.
Gene expression array was carried out on 48 stage 4 tumors and 9 remission marrows using the Affymetrix U95 gene chip. Thirty-four genes with a tumor-to-marrow expression ratio higher than tyrosine hydroxylase were identified. Quantitative reverse transcription-PCR was done on all 34 genes to study the dynamic range of tumor cell detection and the expression of these genes in normal marrow/blood samples and in stage 4 neuroblastoma tumors. Top ranking markers were then tested for prognostic significance in the marrows of stage 4 patients collected from the same treatment protocol after two cycles of immunotherapy.
Based on sensitivity assays, 8 top-ranking markers were identified: CCND1, CRMP1, DDC, GABRB3, ISL1, KIF1A, PHOX2B, and TACC2. They were abundantly expressed in stage IV neuroblastoma tumors (n=20) and had low to no detection in normal marrow/blood samples (n=20). Moreover, expression of CCND1, DDC, GABRB3, ISL1, KIF1A, and PHOX2B in 116 marrows sampled after two treatment cycles was highly prognostic of progression-free and overall survival (P<0.001).
Marker discovery based on differential gene expression profiling, stringent sensitivity and specificity assays, and well-annotated patient samples can rapidly prioritize and identify potential MRD markers of neuroblastoma.

  • [Show abstract] [Hide abstract]
    ABSTRACT: LIM homeobox genes are one of the most important subfamilies of homeobox genes which encode LIM-homeodomain (LIM-HD) proteins featuring two LIM domains in their amino termini and a centrally located HD that is used to interact with specific DNA elements in target genes. Numerous studies have reported their fundamental roles in the development of various organisms; however, little is known about their functions in cancer. Recently, research has shown that LIM homeobox genes also play an important role in cancer development. Among 12 human LIM homeobox genes, 10 LIM-HD proteins have been reported to be associated with cancer. In the present review, we mainly summarize the functions of these genes in various types of cancer and their potential as biomarkers and the related challenges. More in-depth research concerning LIM homeobox genes in cancer from a signaling pathway perspective may help to understand tumor profiles, establish biomarkers and guide choices for combinatorial drug therapies.
    Oncology Reports 03/2014; 31(5). DOI:10.3892/or.2014.3112 · 2.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Anti-GD2 murine antibody 3F8 plus subcutaneously-administered (sc) granulocyte-macrophage colony-stimulating factor (GM-CSF) was used against primary refractory neuroblastoma in metastatic osteomedullary sites. Large study size and long follow-up allowed assessment of prognostic factors in a multivariate analysis not reported with other anti-GD2 antibodies. In a phase II trial, 79 patients without prior progressive disease were treated for persistent osteomedullary neuroblastoma documented by histology and/or metaiodobenzyl-guanidine (MIBG) scan. In the absence of human anti-mouse antibody, 3F8+scGM-CSF cycles were repeated up to 24 months. Minimal residual disease (MRD) in bone marrow was measured by quantitative reverse transcription-polymerase chain reaction pre-enrollment and post-cycle #2, before initiation of 13-cis-retinoic acid. Study endpoints were: 1) progression-free survival (PFS) compared with the predecessor trial of 3F8 plus intravenously-administered (iv) GM-CSF (26 patients), and 2) impact of MRD on PFS. Using all 105 patients from the two consecutive 3F8+GM-CSF trials, prognostic factors were analyzed by multivariate Cox regression model. Complete response rates to 3F8+scGM-CSF were 87% by histology and 38% by MIBG. Five-year PFS was 24%±6% which was significantly superior to 11%±7% with 3F8+ivGM-CSF (p=0.002). In the multivariate analysis, significantly better PFS was associated with R/R or H/R FCGR2A polymorphism, sc route of GM-CSF, and early MRD response. MYCN amplification was not prognostic. Complement consumption was similar with either route of GM-CSF. Toxicities were manageable, allowing outpatient treatment. 3F8+scGM-CSF is highly active against chemoresistant osteomedullary neuroblastoma. MRD response may be an indicator of tumor sensitivity to anti-GD2 immunotherapy. Correlative studies highlight the anti-neoplastic potency of myeloid effectors. © 2014 Wiley Periodicals, Inc.
    International Journal of Cancer 11/2014; 135(9). DOI:10.1002/ijc.28851 · 5.01 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Neuroblastoma (NB), accounting for 10% of childhood cancers, exhibits aberrant cell-surface glycosylation patterns. There is evidence that changes in glycolipids and protein glycosylation pathways are associated to NB biological behavior. Polysialic acid (PSA) interferes with cellular adhesion, and correlates with NB progression and poor prognosis, as well as the expression of sialyltransferase STX, the key enzyme responsible for PSA synthesis. Galectin-1 and gangliosides, overexpressed and actively shedded by tumor cells, can modulate normal cells present in the tumor microenvironment, favoring angiogenesis and immunological escape. Different glycosyltransferases are emerging as tumor markers and potential molecular targets. Immunotherapy targeting disialoganglioside GD2 rises as an important treatment option. One anti-GD2 antibody (ch14.18), combined with IL-2 and GM-CSF, significantly improves survival for high-risk NB patients. This review summarizes our current knowledge on NB glycobiology, highlighting the molecular basis by which carbohydrates and protein-carbohydrate interactions impact on biological behavior and patient clinical outcome.
    Frontiers in Oncology 07/2014; 4:114. DOI:10.3389/fonc.2014.00114


Available from